https://www.selleckchem.com/products/sc79.html
Treatment with hypomethylating agents (HMAs) azacitidine or decitabine is the current standard of care for high risk myelodysplastic syndromes (MDSs) but is associated with low rates of response. The limited number of treatment options for patients with high risk MDS highlights a need for new therapeutic options. Venetoclax is an inhibitor of the BCL-2 protein which, when combined with an HMA, has shown high response rates in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of high risk MDS patients

https://www.selleckchem.com/pr....oducts/taurocholic-a
Besides, ions secretion capacity and Na+ concentration in leaf and root increased, but K+ concentration together with leaf and root K+/Na+ ratios decreased with the increasing concentration of the salinity. However, the salt-tolerant species exhibited strong K+ absorption and transportation ability and a high salt secretion capacity. The results indicated that growth traits and ions regulation were related to variability in tolerance of diverse zoysiagrasses to salt stress.Primary skin amyloidosis is a chron